TG Therapeutics, Inc. (NASDAQ: TGTX) stands out in the biotechnology sector with a market capitalization of $4.69 billion, making it an intriguing prospect for investors seeking exposure to the healthcare industry. As a key player in the biopharmaceutical industry, TG Therapeutics is focused on developing innovative treatments for B-cell mediated diseases, primarily with its flagship product, BRIUMVI, designed for patients suffering from various forms of multiple sclerosis.

The company’s stock is currently trading at $29.53, near the lower end of its 52-week range of $26.39 to $45.51. However, the average analyst target price of $44.43 suggests a potential upside of approximately 50.45%, a compelling figure for investors looking…